{"id":"cisplatin-carboplatin-plus-etoposide","safety":{"commonSideEffects":[{"rate":"60-90","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"70-90","effect":"Nausea and vomiting"},{"rate":"20-30","effect":"Nephrotoxicity (cisplatin)"},{"rate":"10-30","effect":"Ototoxicity (cisplatin)"},{"rate":"10-20","effect":"Peripheral neuropathy"},{"rate":"40-60","effect":"Alopecia"},{"rate":"20-40","effect":"Mucositis"},{"rate":"1-5","effect":"Secondary malignancy (etoposide)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cisplatin and carboplatin are alkylating agents that form covalent bonds with DNA, creating interstrand and intrastrand cross-links that prevent DNA replication and transcription, leading to cell death. Etoposide inhibits topoisomerase II, an enzyme essential for DNA unwinding, thereby trapping the enzyme on DNA and causing double-strand breaks. Together, these agents provide synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"This combination uses platinum-based chemotherapy agents (cisplatin or carboplatin) to cross-link DNA, combined with etoposide, a topoisomerase II inhibitor that prevents DNA unwinding and repair.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:02.025Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Small cell lung cancer"},{"name":"Germ cell tumors"},{"name":"Lymphomas"}]},"trialDetails":[{"nctId":"NCT07055581","phase":"PHASE2","title":"Durvalumab as Consolidation for Patients LS-SCLC","status":"RECRUITING","sponsor":"Qian Chu","startDate":"2026-02-24","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":100},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT05058651","phase":"PHASE2, PHASE3","title":"Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-28","conditions":"Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma","enrollment":189},{"nctId":"NCT04092283","phase":"PHASE3","title":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-29","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":660},{"nctId":"NCT05019716","phase":"PHASE1, PHASE2","title":"Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-13","conditions":"Advanced NUT Carcinoma, Metastatic NUT Carcinoma, Unresectable NUT Carcinoma","enrollment":36},{"nctId":"NCT03811002","phase":"PHASE3","title":"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-26","conditions":"Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8","enrollment":544},{"nctId":"NCT05903092","phase":"PHASE2","title":"MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer","status":"SUSPENDED","sponsor":"Hirva Mamdani","startDate":"2023-09-26","conditions":"Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer","enrollment":84},{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT07477756","phase":"","title":"A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-09-04","conditions":"Prostate Cancer","enrollment":1247},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT06157827","phase":"PHASE1, PHASE2","title":"A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2023-12-08","conditions":"Advanced Neuroendocrine Carcinoma","enrollment":178},{"nctId":"NCT06193759","phase":"PHASE1","title":"Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2024-09-20","conditions":"Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS, Embryonal Tumor With Multilayered Rosettes","enrollment":12},{"nctId":"NCT02402920","phase":"PHASE1","title":"Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-07-22","conditions":"Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma, Neuroendocrine Neoplasm","enrollment":83},{"nctId":"NCT06719700","phase":"PHASE2","title":"Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-30","conditions":"Toripalimab, Surufatinib, Chemoradiotherapy","enrollment":47},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT03067181","phase":"PHASE3","title":"Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-05-25","conditions":"Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor","enrollment":1780},{"nctId":"NCT04602533","phase":"PHASE2","title":"Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Michael Hopp","startDate":"2020-12-21","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":105},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT05403723","phase":"PHASE1","title":"Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC","status":"SUSPENDED","sponsor":"University of Maryland, Baltimore","startDate":"2026-06-30","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":50},{"nctId":"NCT06712355","phase":"PHASE3","title":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-02-03","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":621},{"nctId":"NCT05535166","phase":"PHASE2","title":"Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-12-20","conditions":"Medulloblastoma","enrollment":130},{"nctId":"NCT02875314","phase":"PHASE4","title":"HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parth Patel","startDate":"2015-09","conditions":"Medulloblastoma, Central Nervous System Embryonal Tumors","enrollment":250},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":"B-Cell Non-Hodgkin Lymphoma (B-NHL)","enrollment":216},{"nctId":"NCT07381543","phase":"PHASE2","title":"Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03","conditions":"Localized Small Cell Lung Cancer","enrollment":76},{"nctId":"NCT07381829","phase":"PHASE1","title":"A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer","status":"RECRUITING","sponsor":"HC Biopharma Inc.","startDate":"2025-10-27","conditions":"Advanced Solid Tumor Cancer","enrollment":328},{"nctId":"NCT06564844","phase":"PHASE3","title":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-10-15","conditions":"Non-small Cell Lung Cancer","enrollment":24},{"nctId":"NCT00336024","phase":"PHASE3","title":"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-10-22","conditions":"Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified","enrollment":91},{"nctId":"NCT07358676","phase":"PHASE2","title":"A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-01","conditions":"Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage","enrollment":25},{"nctId":"NCT03937843","phase":"PHASE2","title":"Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2019-07-29","conditions":"Seminoma, Testicular Cancer","enrollment":135},{"nctId":"NCT05594290","phase":"PHASE2","title":"Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2022-12-07","conditions":"Merkel Cell Carcinoma","enrollment":36},{"nctId":"NCT05624996","phase":"PHASE3","title":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-07-12","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":474},{"nctId":"NCT05353257","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2022-05-17","conditions":"Limited-Stage Small Cell Lung Cancer","enrollment":511},{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT07268040","phase":"PHASE2","title":"A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2025-12-23","conditions":"Malignant Solid Tumors","enrollment":400},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT06077500","phase":"PHASE1","title":"DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-02-14","conditions":"Small Cell Lung Carcinoma (SCLC)","enrollment":45},{"nctId":"NCT04699838","phase":"PHASE2","title":"Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Muhammad Furqan","startDate":"2021-04-20","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT05470595","phase":"PHASE2","title":"A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung","status":"ACTIVE_NOT_RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2022-01-18","conditions":"Large Cell Neuroendocrine Carcinoma of the Lung","enrollment":67},{"nctId":"NCT02595424","phase":"PHASE2","title":"Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2016-04-06","conditions":"Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma","enrollment":67},{"nctId":"NCT03533582","phase":"PHASE3","title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-24","conditions":"Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma","enrollment":537},{"nctId":"NCT06132113","phase":"PHASE1","title":"DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-01-22","conditions":"Neuroendocrine Neoplasms","enrollment":55},{"nctId":"NCT04745689","phase":"PHASE2","title":"Study of AZD2811 + Durvalumab in ES-SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-02-23","conditions":"Small-Cell Lung Cancer","enrollment":31},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT07136285","phase":"PHASE1, PHASE2","title":"Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC","status":"RECRUITING","sponsor":"Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.","startDate":"2023-07-24","conditions":"SCLC, Extensive Stage","enrollment":27},{"nctId":"NCT05664971","phase":"PHASE1, PHASE2","title":"JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-02-09","conditions":"Advanced Lung Cancer","enrollment":119},{"nctId":"NCT06333314","phase":"PHASE2","title":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-23","conditions":"Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma","enrollment":120},{"nctId":"NCT03391466","phase":"PHASE3","title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2018-01-25","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":359},{"nctId":"NCT03132532","phase":"PHASE2","title":"Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-07-31","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":20},{"nctId":"NCT03582475","phase":"PHASE1","title":"Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-01-11","conditions":"Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma","enrollment":15},{"nctId":"NCT03519971","phase":"PHASE3","title":"Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-29","conditions":"Non-Small Cell Lung Cancer","enrollment":328},{"nctId":"NCT01096368","phase":"PHASE3","title":"Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2010-05-07","conditions":"Anaplastic Ependymoma, Brain Ependymoma, Cellular Ependymoma","enrollment":479},{"nctId":"NCT03043872","phase":"PHASE3","title":"Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-03-27","conditions":"Small Cell Lung Carcinoma Extensive Disease","enrollment":987},{"nctId":"NCT02964013","phase":"PHASE1","title":"Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-12-13","conditions":"Neoplasms","enrollment":474},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":"Ganglioneuroblastoma, High Risk Neuroblastoma","enrollment":42},{"nctId":"NCT04325425","phase":"PHASE2","title":"Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-09-01","conditions":"Neuroendocrine Carcinoma","enrollment":218},{"nctId":"NCT06838208","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC","status":"RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-02-25","conditions":"Extensive-stage Small Cell Lung Cancer (ES-SCLC)","enrollment":56},{"nctId":"NCT06448910","phase":"PHASE2","title":"Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2024-07-01","conditions":"NSCLC, Locally Advanced Lung Carcinoma","enrollment":41},{"nctId":"NCT07187960","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2025-11","conditions":"Follicular Lymphoma","enrollment":228},{"nctId":"NCT06144736","phase":"PHASE2","title":"PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND","status":"RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2023-08-28","conditions":"Seminoma","enrollment":60},{"nctId":"NCT07155122","phase":"PHASE2","title":"Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-09-01","conditions":"Small-Cell Carcinoma of the Esophageal","enrollment":15},{"nctId":"NCT06865339","phase":"PHASE2","title":"Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Nitin Ohri","startDate":"2025-08-07","conditions":"NSCLC, Locally Advanced","enrollment":76},{"nctId":"NCT01770418","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Proton Collaborative Group","startDate":"2013-03","conditions":"Lung Neoplasms","enrollment":32},{"nctId":"NCT02820857","phase":"PHASE2","title":"Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2017-09-04","conditions":"Neuroendocrine Carcinomas","enrollment":153},{"nctId":"NCT07141771","phase":"PHASE1, PHASE2","title":"An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-12-31","conditions":"SCLC, Extensive Stage","enrollment":100},{"nctId":"NCT05796089","phase":"PHASE2","title":"Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2022-01-01","conditions":"Extensive-Stage Small-Cell Lung Cancer","enrollment":35},{"nctId":"NCT04047862","phase":"PHASE1","title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-08-15","conditions":"Locally Advanced and Metastatic Solid Tumors","enrollment":446},{"nctId":"NCT07138001","phase":"PHASE2","title":"Phase 2 Clinical Trial of KH617","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Honghe Biotechnology Co., Ltd.","startDate":"2025-08","conditions":"Recurrent Glioblastoma","enrollment":60},{"nctId":"NCT04380636","phase":"PHASE3","title":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-06","conditions":"Lung Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":870},{"nctId":"NCT07109401","phase":"PHASE2","title":"Perioperative Immunotherapy for Resectable Limited-Stage SCLC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-01","conditions":"Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma, Resectable Small Cell Lung Cancer","enrollment":37},{"nctId":"NCT05298423","phase":"PHASE3","title":"Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-05-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":611},{"nctId":"NCT07091305","phase":"PHASE2","title":"A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-07-01","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy, Induction Therapy","enrollment":28},{"nctId":"NCT07083375","phase":"PHASE2","title":"A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Zhijie Wang","startDate":"2025-08-01","conditions":"Extensive Small Cell Lung Cancer","enrollment":56},{"nctId":"NCT04268121","phase":"PHASE2","title":"Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas","status":"RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2021-01-05","conditions":"Neuroendocrine Carcinoma, Digestive Cancer","enrollment":78},{"nctId":"NCT04924101","phase":"PHASE2","title":"Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-07-15","conditions":"Small Cell Lung Cancer","enrollment":126},{"nctId":"NCT07061535","phase":"PHASE2","title":"Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08-01","conditions":"Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer","enrollment":40},{"nctId":"NCT05224141","phase":"PHASE3","title":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-24","conditions":"Small Cell Lung Carcinoma","enrollment":460},{"nctId":"NCT03382561","phase":"PHASE2","title":"Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-21","conditions":"Extensive Stage Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma","enrollment":160},{"nctId":"NCT03567642","phase":"PHASE1","title":"A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-06-12","conditions":"Lung Cancer","enrollment":11},{"nctId":"NCT04624204","phase":"PHASE3","title":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-08","conditions":"Small Cell Lung Cancer","enrollment":672},{"nctId":"NCT05312671","phase":"PHASE2","title":"Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-06-27","conditions":"Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder","enrollment":63},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT05623319","phase":"PHASE2","title":"Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2023-03-27","conditions":"SCLC,Extensive Stage","enrollment":60},{"nctId":"NCT04905316","phase":"PHASE2","title":"A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-21","conditions":"Non-small Cell Lung Cancer","enrollment":41},{"nctId":"NCT06311981","phase":"PHASE2","title":"Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2024-08-08","conditions":"Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy","enrollment":29},{"nctId":"NCT06311968","phase":"PHASE2","title":"The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2024-05-06","conditions":"Thymus Epithelial Tumor, Proton Radiotherapy, Radiation Toxicity","enrollment":55},{"nctId":"NCT06186726","phase":"PHASE2","title":"Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2024-01-26","conditions":"Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy","enrollment":48},{"nctId":"NCT06311955","phase":"PHASE2","title":"Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2025-07-01","conditions":"Thymic Epithelial Tumor, Radiotherapy Side Effect, Carbon Ion Radiotheray","enrollment":48},{"nctId":"NCT07008716","phase":"PHASE3","title":"Omitting CTV for Primary Tumor in LS-SCLC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-03","conditions":"SCLC, Limited Stage, Radiation Exposure, Radiotherapy Side Effect","enrollment":852},{"nctId":"NCT06140407","phase":"PHASE2","title":"Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2024-02-14","conditions":"Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer, Stage II Lung Cancer","enrollment":1},{"nctId":"NCT04774380","phase":"PHASE3","title":"Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-11-11","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":152},{"nctId":"NCT06419179","phase":"PHASE2","title":"Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)","status":"ENROLLING_BY_INVITATION","sponsor":"University of Cologne","startDate":"2024-10-09","conditions":"Small Cell Lung Carcinoma","enrollment":29},{"nctId":"NCT06978153","phase":"PHASE2","title":"This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2025-05-20","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":66},{"nctId":"NCT05705687","phase":"NA","title":"Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2023-05-05","conditions":"Non-Seminomatous Germ Cell Tumor","enrollment":150},{"nctId":"NCT04668365","phase":"PHASE2","title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"Henan Cancer Hospital","startDate":"2020-12-25","conditions":"Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation","enrollment":59},{"nctId":"NCT06931145","phase":"PHASE4","title":"Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-04-15","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT04870112","phase":"PHASE1","title":"A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-06-28","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer","enrollment":18},{"nctId":"NCT05384015","phase":"PHASE2","title":"Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Fundación GECP","startDate":"2022-11-07","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":46},{"nctId":"NCT06911606","phase":"PHASE2","title":"Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-05-22","conditions":"SCLC, Limited Stage","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":53,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cisplatin/carboplatin plus etoposide","genericName":"Cisplatin/carboplatin plus etoposide","companyName":"EpicentRx, Inc.","companyId":"epicentrx-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses platinum-based chemotherapy agents (cisplatin or carboplatin) to cross-link DNA, combined with etoposide, a topoisomerase II inhibitor that prevents DNA unwinding and repair. Used for Small cell lung cancer, Germ cell tumors, Lymphomas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}